220 related articles for article (PubMed ID: 34873031)
21. NKG2D stimulated T-cell autoreactivity in giant cell arteritis and polymyalgia rheumatica.
Dejaco C; Duftner C; Al-Massad J; Wagner AD; Park JK; Fessler J; Aigelsreiter A; Hafner F; Vega S; Sterlacci W; Grubeck-Loebenstein B; Tzankov A; Ness T; Boiardi L; Salvarani C; Schirmer M
Ann Rheum Dis; 2013 Nov; 72(11):1852-9. PubMed ID: 23417963
[TBL] [Abstract][Full Text] [Related]
22. The NKG2D ligand ULBP4 is not expressed by human monocytes.
Lazarova M; Kim Y; Steinle A
PLoS One; 2021; 16(2):e0246726. PubMed ID: 33556116
[TBL] [Abstract][Full Text] [Related]
23. ULBP4 is a novel ligand for human NKG2D.
Chalupny NJ; Sutherland CL; Lawrence WA; Rein-Weston A; Cosman D
Biochem Biophys Res Commun; 2003 May; 305(1):129-35. PubMed ID: 12732206
[TBL] [Abstract][Full Text] [Related]
24. Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK- cell lysis.
Cerboni C; Zingoni A; Cippitelli M; Piccoli M; Frati L; Santoni A
Blood; 2007 Jul; 110(2):606-15. PubMed ID: 17405908
[TBL] [Abstract][Full Text] [Related]
25. CD8
Lerner EC; Woroniecka KI; D'Anniballe VM; Wilkinson DS; Mohan AA; Lorrey SJ; Waibl-Polania J; Wachsmuth LP; Miggelbrink AM; Jackson JD; Cui X; Raj JA; Tomaszewski WH; Cook SL; Sampson JH; Patel AP; Khasraw M; Gunn MD; Fecci PE
Nat Cancer; 2023 Sep; 4(9):1258-1272. PubMed ID: 37537301
[TBL] [Abstract][Full Text] [Related]
26. Characterization of 5' promoter and exon 1-3 polymorphism of the RAET1E gene.
Cox ST; Pearson H; Laza-Briviesca R; Pesoa S; Vullo C; Madrigal JA; Saudemont A
Hum Immunol; 2016 Jan; 77(1):96-103. PubMed ID: 26519211
[TBL] [Abstract][Full Text] [Related]
27. NKG2D is a costimulatory receptor for human naive CD8+ T cells.
Maasho K; Opoku-Anane J; Marusina AI; Coligan JE; Borrego F
J Immunol; 2005 Apr; 174(8):4480-4. PubMed ID: 15814668
[TBL] [Abstract][Full Text] [Related]
28. Development of small molecule inhibitors of natural killer group 2D receptor (NKG2D).
Wang J; Nakafuku KM; Ziff J; Gelin CF; Gholami H; Thompson AA; Karpowich NK; Limon L; Coate HR; Damm-Ganamet KL; Shih AY; Grant JC; Côte M; Mak PA; Pascual HA; Rives ML; Edwards JP; Venable JD; Venkatesan H; Shi Z; Allen SJ; Sharma S; Kung PP; Shireman BT
Bioorg Med Chem Lett; 2023 Nov; 96():129492. PubMed ID: 37778428
[TBL] [Abstract][Full Text] [Related]
29. NKG2D-dependent activation of dendritic epidermal T cells in contact hypersensitivity.
Nielsen MM; Dyring-Andersen B; Schmidt JD; Witherden D; Lovato P; Woetmann A; Ødum N; Poulsen SS; Havran WL; Geisler C; Bonefeld CM
J Invest Dermatol; 2015 May; 135(5):1311-1319. PubMed ID: 25634359
[TBL] [Abstract][Full Text] [Related]
30. NKG2D Defines a Subset of Skin Effector Memory CD8 T Cells with Proinflammatory Functions in Vitiligo.
Jacquemin C; Martins C; Lucchese F; Thiolat D; Taieb A; Seneschal J; Boniface K
J Invest Dermatol; 2020 Jun; 140(6):1143-1153.e5. PubMed ID: 31877315
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical validation and expression profiling of NKG2D ligands in a wide spectrum of human epithelial neoplasms.
Fujita H; Hatanaka Y; Sutoh Y; Suzuki Y; Oba K; Hatanaka KC; Mitsuhashi T; Otsuka N; Fugo K; Kasahara M; Matsuno Y
J Histochem Cytochem; 2015 Mar; 63(3):217-27. PubMed ID: 25473094
[TBL] [Abstract][Full Text] [Related]
32. Induction of NKG2D ligand expression on tumor cells by CD8
Hu J; Xia X; Gorlick R; Li S
Oncogene; 2019 Dec; 38(49):7433-7446. PubMed ID: 31427736
[TBL] [Abstract][Full Text] [Related]
33. A nanoscale reorganization of the IL-15 receptor is triggered by NKG2D in a ligand-dependent manner.
Bálint Š; Lopes FB; Davis DM
Sci Signal; 2018 Apr; 11(525):. PubMed ID: 29636390
[TBL] [Abstract][Full Text] [Related]
34. Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity.
Wiendl H; Feger U; Mittelbronn M; Jack C; Schreiner B; Stadelmann C; Antel J; Brueck W; Meyermann R; Bar-Or A; Kieseier BC; Weller M
Brain; 2005 Nov; 128(Pt 11):2689-704. PubMed ID: 16123145
[TBL] [Abstract][Full Text] [Related]
35. Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion.
Lundholm M; Schröder M; Nagaeva O; Baranov V; Widmark A; Mincheva-Nilsson L; Wikström P
PLoS One; 2014; 9(9):e108925. PubMed ID: 25268476
[TBL] [Abstract][Full Text] [Related]
36. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
Song H; Kim J; Cosman D; Choi I
Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603
[TBL] [Abstract][Full Text] [Related]
37. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia.
Salih HR; Antropius H; Gieseke F; Lutz SZ; Kanz L; Rammensee HG; Steinle A
Blood; 2003 Aug; 102(4):1389-96. PubMed ID: 12714493
[TBL] [Abstract][Full Text] [Related]
38. TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors.
Maccalli C; Scaramuzza S; Parmiani G
Cancer Immunol Immunother; 2009 May; 58(5):801-8. PubMed ID: 19089424
[TBL] [Abstract][Full Text] [Related]
39. The UL16-binding proteins, a novel family of MHC class I-related ligands for NKG2D, activate natural killer cell functions.
Sutherland CL; Chalupny NJ; Cosman D
Immunol Rev; 2001 Jun; 181():185-92. PubMed ID: 11513139
[TBL] [Abstract][Full Text] [Related]
40. HLA-E restricted CD8+ T cell subsets are phenotypically altered in multiple sclerosis patients.
Pannemans K; Broux B; Goris A; Dubois B; Broekmans T; Van Wijmeersch B; Geraghty D; Stinissen P; Hellings N
Mult Scler; 2014 Jun; 20(7):790-801. PubMed ID: 24144875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
